High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801

Journal of Clinical Oncology

Volumn 19, Issue 9, 2001, Pages 2370-2380

  Kirkwood, J M ^a   Ibrahim, J G ^a   Sosman, J A ^a   Sondak, V K ^a   Agarwala, S S ^a   Ernstoff, M S ^a   Rao, U ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; QS 21;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 0035339880     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.9.2370     Document Type: Article

References (42)

1. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
2. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
3. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b
4. Neurotoxicity of interferon-alpha in melanoma therapy: Results from a randomized controlled trial
5. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes
6. Adjuvant therapy for malignant melanoma
7. Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial
8. Irradiated autologous melanoma cells from short-term tissue culture as vaccines for patients with metastatic melanoma
9. Regression of lung metastases after immunotherapy with autologous, DNP-modified melanoma vaccine
10. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
11. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
12. Active specific immunotherapy using attenuated autologous tumor cells in malignant melanoma
13. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma
14. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
15. Phase I/II trial of a shed, polyvalent, melanoma vaccine combined with interferon alfa-2b in stage IV melanoma
16. Phase 3, double-blind, trial of a shed, polyvalent, melanoma vaccine in stage III melanoma
17. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival
18. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography
19. Ganglioside vaccines with emphasis on GM2
20. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside
21. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
22. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
23. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study
24. GM2-KLH/QS-21 (GMK) vaccine induces anti-GM2 antibodies in melanoma patients that bind to melanoma cells and demonstrate complement-mediated cytotoxicity (CMC) and antibody dependent cellular cytotoxicity (ADCC) unaffected by concurrent interferon treatment
25. A new American Joint Committee on Cancer staging system for cutaneous melanoma
26. Principles of the clinical evaluation of biologic agents
27. The large sample distribution of the weighted log rank statistic under general local alternatives
28. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696
29. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
30. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma
31. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment
32. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
33. Immunologic and therapeutic evatuation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
34. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: Differential immunogenicity of Melan-A27-35 and Melan-A26-35
35. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
36. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
37. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma
38. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma
39. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene
40. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy
41. Melan-A/MART-l(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
42. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pme117/gp100